We came into the drug discovery space at the perfect time where researchers were finally ready to transition to quantitative tissue analysis.
(PRWEB) August 01, 2018
Visikol CEO Dr. Michael Johnson has announced that through the rapid adoption of its 3Screen™ drug discovery services and strong pharmaceutical company partnerships that Visikol will far exceed its original 2018 revenue projections.
Over the last two years, Visikol has been focused on developing its suite of digital pathology tools, whole mount imaging techniques and advanced 3D cell culture assays. These tools have all been developed with one goal in mind which is to accelerate the pharmaceutical industries transition in the drug discovery space from qualitative tissue analysis to quantitative analysis. The company has leveraged these tools through its 3Screen™ service offering to offer pharmaceutical companies best-in-class drug discovery services to answer complex research questions and to help develop life-saving therapeutics such as Enzyvant’s RVT-802 treatment for Complete DiGeorge Syndrome.
“I have been very happy with our progress during the first half of 2018 and have been excited to see pharmaceutical companies so readily and quickly adopting our digital pathology tools and advanced assays in their drug discovery efforts” described Visikol CEO Dr. Michael Johnson. Visikol has grown rapidly during 2018 and has been able to assist multiple pharmaceutical company clients with the transition from qualitative pathology to quantitative digital pathology by providing a suite of services that include slide scanning all the way to validated software development. These services enable clients to extract hundreds of features from tissue slides for quantitative analysis instead of the traditional approach of manual evaluation of a few features by eye. Additionally, Visikol has pioneered 3D tissue imaging and analysis using its patented tissue clearing technique and suite of image analysis algorithms that allow for complex tissue features such as vasculature to be quantified.
“I think we came into the drug discovery space at the perfect time where researchers were finally ready to transition to quantitative tissue analysis and we have provided just the right portfolio of services in this space to help with this transition” described Visikol CSO Dr. Tom Villani. Visikol’s 3Screen™ portfolio of services has been disruptive in the drug discovery marketplace since its introduction and is allowing for new questions to be asked and answered as well as therapeutic development to be accelerated. Interest in Visikol’s 3Screen™ services has exceeded its expectations in 2018 and the company plans to further build out its capabilities to better meet this need in the second half of 2018.
Visikol’s efforts in this space have not gone unnoticed whereas their unique approach to drug discovery and implementation of cutting-edge technologies recently drew the attention of Forbes who highlighted Visikol through their Passion and Innovation video series. Forbes highlighted Visikol for their innovative approach to improving therapeutic development and their passion for helping pharmaceutical companies bring therapeutics to patients in need.
Visikol is focused on accelerating drug discovery through quantitative histopathology and using their patented Visikol HISTO tissue clearing technology to transform tissues into three dimensional data sets that can be mined for actionable insights. When paired with fluorescent labeling and 3D microscopy, Visikol® HISTO™ allows tissues such as 3D cell culture models or whole tissues to be imaged in their entirety in 3D. Visikol has leveraged this technology to launch 3Screen™ which is a high-throughput 3D imaging platform capable of transforming tissues into 3D data sets and answering complex biological questions. The addition of 3D histological information to the drug discovery workflow allows for complex features such as vasculature networks to be quantitatively analyzed in 3D or for the penetration kinetics of antibodies into tumor models to be understood. The company currently offers 3Screen™ as a service to pharmaceutical/biotech companies and is continually focused on improving the platform as well as building out a suite of standardized assays. In addition to this service offering, Visikol also sells various tissue clearing reagents and kits for academic researchers that are interested in adopting the approach into their own workflows. For more information about Visikol® or 3Screen™, please visit our website at visikol.com.
For additional assistance, journalists, investors and analysts may contact:
Dr. Michael Johnson
Chief Executive Officer